(Q36560412)

English

Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes

scientific article published on 18 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 August 2017

Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes (English)

1 reference

Europe PubMed Central

14 August 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Kohei Kaku

1

1 reference

Europe PubMed Central

14 August 2017

Takahiro Araki

2

1 reference

Europe PubMed Central

14 August 2017

Ryoji Yoshinaka

3

1 reference

Europe PubMed Central

14 August 2017

language of work or name

0 references

publication date

18 October 2012

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

36

1 reference

Europe PubMed Central

14 August 2017

2

1 reference

Europe PubMed Central

14 August 2017

245-250

1 reference

Europe PubMed Central

14 August 2017

copyright license

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

1 September 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3554318

30 September 2017

International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3554318

30 September 2017

GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3554318

30 September 2017

Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3554318

30 September 2017

International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3554318

30 September 2017

The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3554318

30 September 2017

Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3554318

30 September 2017

Pleiotropic effects of fatty acids on pancreatic beta-cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3554318

30 September 2017

Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3554318

28 June 2018

TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23086138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/23086138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2337/DC12-0872

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

1 reference

Europe PubMed Central

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36560412&oldid=1866337844"